The National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) is funding a $28-million multicenter trial of antiviral drugs for the treatment of chronic infection with the hepatitis C virus (HCV). The 8-year trial is designed to help researchers determine if long-term treatment with such drugs can help delay or prevent progression of liver disease in patients infected with HCV.
The study is also intended to gather information on the natural history of HCV infection and help researchers identify factors that predict or correlate with HCV-related liver damage.
Stephenson J. Hepatitis C Trial. JAMA. 1999;282(11):1028. doi:10.1001/jama.282.11.1028-JHA90007-4-1
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: